20May/14

InterMune Announces Additional Pirfenidone Data in Idiopathic Pulmonary … – MarketWatch


Drug Discovery & Development
InterMune Announces Additional Pirfenidone Data in Idiopathic Pulmonary
MarketWatch
Ltd. Under different trade names, pirfenidone is also approved for the treatment of IPF in China, India, Argentina and Mexico. Pirfenidone is not approved for sale in the United States. About IPF Idiopathic pulmonary fibrosis (IPF) is an irreversible
InterMune Up on Esbriet Data Presentation – Analyst BlogNASDAQ
Phase 3 ASCEND Study of Pirfenidone in Idiopathic Pulmonary Fibrosis Stockhouse

all 98 news articles »